Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: Some Companies Having Trouble Performing Design Control Activities

This article was originally published in The Silver Sheet

Executive Summary

DESIGN CONTROL CAN PROVE PROBLEMATIC for medical device manufacturers that don't have highly skilled engineers on staff, says CDRH official Al Taylor, speculating that firms that skimp on engineering resources may have played a role in last year's increase in design control citations on FDA warning letters. In particular, FDA has found that manufacturers are struggling with design verification, design validation and design change activities, FDA GMP Expert Kim Trautman says. She adds that last year's jump in recalls suggests that firms aren't “doing the amount of work that [they] need to in this area.” Meanwhile, device manufacturers Thoratec, Philips Consumer Healthcare Solutions and Hitachi Chemical Diagnostics share best practices for design control.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel